Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: A prospective evaluation of prognostic value in 94 patients

Brijesh Arora, Shireen Sirhan, James Hoyer, Ruben A. Mesa, Ayalew Tefferi

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

In a prospective study, peripheral blood (PB) CD34 count, bone marrow histology and other clinical parameters were concurrently evaluated in 94 patients with myelofibrosis with myeloid metaplasia (MMM) and the study cohort followed for a minimum of 3 years. Median PB CD34 count was 0.0547 × 109/1 (range 0.5-345 × 109/1) with 86% of the patients displaying above normal levels (>0.005 × 109/l). In a multivariate analysis, only leucocyte count and PB blast percentage correlated with PB CD34 count in an independent and consistent fashion. After a median follow up of 41 months from PB CD34 analysis, 43 patients (46%) have died with a projected 5-year survival of 50%. In a univariate analysis, PB CD34 count above 0.1 × 109/l correlated significantly with shortened survival, leukaemic transformation and clinical progression. However, such statistical significance was lost during multivariate analysis, which identified only anaemia and leucocytosis as independent risk factors for shortened survival. Furthermore, sequential analysis of PB CD34 count was performed in 53 patients and 43% of those who progressed clinically did not display a concomitant rise in their PB CD34 count. The current prospective study does not support an independent prognostic value for PB CD34 count in MMM.

Original languageEnglish (US)
Pages (from-to)42-48
Number of pages7
JournalBritish Journal of Haematology
Volume128
Issue number1
DOIs
StatePublished - Jan 2005

Fingerprint

Primary Myelofibrosis
Survival
Multivariate Analysis
Prospective Studies
Leukocytosis
Leukocyte Count
Anemia
Histology
Cohort Studies
Bone Marrow

Keywords

  • CD34 count
  • Myelofibrosis
  • Prognosis

ASJC Scopus subject areas

  • Hematology

Cite this

Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia : A prospective evaluation of prognostic value in 94 patients. / Arora, Brijesh; Sirhan, Shireen; Hoyer, James; Mesa, Ruben A.; Tefferi, Ayalew.

In: British Journal of Haematology, Vol. 128, No. 1, 01.2005, p. 42-48.

Research output: Contribution to journalArticle

@article{b505f41fa0b64415b002ab0d02d2e515,
title = "Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia: A prospective evaluation of prognostic value in 94 patients",
abstract = "In a prospective study, peripheral blood (PB) CD34 count, bone marrow histology and other clinical parameters were concurrently evaluated in 94 patients with myelofibrosis with myeloid metaplasia (MMM) and the study cohort followed for a minimum of 3 years. Median PB CD34 count was 0.0547 × 109/1 (range 0.5-345 × 109/1) with 86{\%} of the patients displaying above normal levels (>0.005 × 109/l). In a multivariate analysis, only leucocyte count and PB blast percentage correlated with PB CD34 count in an independent and consistent fashion. After a median follow up of 41 months from PB CD34 analysis, 43 patients (46{\%}) have died with a projected 5-year survival of 50{\%}. In a univariate analysis, PB CD34 count above 0.1 × 109/l correlated significantly with shortened survival, leukaemic transformation and clinical progression. However, such statistical significance was lost during multivariate analysis, which identified only anaemia and leucocytosis as independent risk factors for shortened survival. Furthermore, sequential analysis of PB CD34 count was performed in 53 patients and 43{\%} of those who progressed clinically did not display a concomitant rise in their PB CD34 count. The current prospective study does not support an independent prognostic value for PB CD34 count in MMM.",
keywords = "CD34 count, Myelofibrosis, Prognosis",
author = "Brijesh Arora and Shireen Sirhan and James Hoyer and Mesa, {Ruben A.} and Ayalew Tefferi",
year = "2005",
month = "1",
doi = "10.1111/j.1365-2141.2004.05280.x",
language = "English (US)",
volume = "128",
pages = "42--48",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Peripheral blood CD34 count in myelofibrosis with myeloid metaplasia

T2 - A prospective evaluation of prognostic value in 94 patients

AU - Arora, Brijesh

AU - Sirhan, Shireen

AU - Hoyer, James

AU - Mesa, Ruben A.

AU - Tefferi, Ayalew

PY - 2005/1

Y1 - 2005/1

N2 - In a prospective study, peripheral blood (PB) CD34 count, bone marrow histology and other clinical parameters were concurrently evaluated in 94 patients with myelofibrosis with myeloid metaplasia (MMM) and the study cohort followed for a minimum of 3 years. Median PB CD34 count was 0.0547 × 109/1 (range 0.5-345 × 109/1) with 86% of the patients displaying above normal levels (>0.005 × 109/l). In a multivariate analysis, only leucocyte count and PB blast percentage correlated with PB CD34 count in an independent and consistent fashion. After a median follow up of 41 months from PB CD34 analysis, 43 patients (46%) have died with a projected 5-year survival of 50%. In a univariate analysis, PB CD34 count above 0.1 × 109/l correlated significantly with shortened survival, leukaemic transformation and clinical progression. However, such statistical significance was lost during multivariate analysis, which identified only anaemia and leucocytosis as independent risk factors for shortened survival. Furthermore, sequential analysis of PB CD34 count was performed in 53 patients and 43% of those who progressed clinically did not display a concomitant rise in their PB CD34 count. The current prospective study does not support an independent prognostic value for PB CD34 count in MMM.

AB - In a prospective study, peripheral blood (PB) CD34 count, bone marrow histology and other clinical parameters were concurrently evaluated in 94 patients with myelofibrosis with myeloid metaplasia (MMM) and the study cohort followed for a minimum of 3 years. Median PB CD34 count was 0.0547 × 109/1 (range 0.5-345 × 109/1) with 86% of the patients displaying above normal levels (>0.005 × 109/l). In a multivariate analysis, only leucocyte count and PB blast percentage correlated with PB CD34 count in an independent and consistent fashion. After a median follow up of 41 months from PB CD34 analysis, 43 patients (46%) have died with a projected 5-year survival of 50%. In a univariate analysis, PB CD34 count above 0.1 × 109/l correlated significantly with shortened survival, leukaemic transformation and clinical progression. However, such statistical significance was lost during multivariate analysis, which identified only anaemia and leucocytosis as independent risk factors for shortened survival. Furthermore, sequential analysis of PB CD34 count was performed in 53 patients and 43% of those who progressed clinically did not display a concomitant rise in their PB CD34 count. The current prospective study does not support an independent prognostic value for PB CD34 count in MMM.

KW - CD34 count

KW - Myelofibrosis

KW - Prognosis

UR - http://www.scopus.com/inward/record.url?scp=12744254920&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12744254920&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2004.05280.x

DO - 10.1111/j.1365-2141.2004.05280.x

M3 - Article

C2 - 15606548

AN - SCOPUS:12744254920

VL - 128

SP - 42

EP - 48

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 1

ER -